Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

Rhea-AI Summary

Alkermes (ALKS) has announced it will host a conference call and webcast on February 12, 2025, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2024 financial results. During the presentation, management will also outline financial expectations for 2025 and provide a company update.

The event will be accessible through the company's website investor section, with a conference call available at +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international participants. A replay will be available approximately two hours after the event.

Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.

News Market Reaction

-0.25%

1 alert

-0.25% News Effect

On the day this news was published, ALKS declined 0.25%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the company.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-fourth-quarter-and-year-end-financial-results-on-feb-12-2025-302368996.html

SOURCE Alkermes plc

FAQ

When will Alkermes (ALKS) report Q4 and full-year 2024 earnings?

Alkermes will report its Q4 and full-year 2024 earnings on February 12, 2025, at 8:00 a.m. ET (1:00 p.m. GMT).

How can investors access ALKS Q4 2024 earnings call?

Investors can access the webcast through Alkermes' website investor section or join the conference call by dialing +1 877 407 2988 (U.S.) or +1 201 389 0923 (international).

What topics will be covered in ALKS February 2025 earnings call?

The call will cover Q4 and year-end 2024 financial results, financial expectations for 2025, and a general company update.

What therapeutic areas does Alkermes (ALKS) focus on?

Alkermes focuses on neuroscience, with products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and is developing treatments for neurological disorders including narcolepsy and idiopathic hypersomnia.